Perrigo plans to launch private-label Aleve in early 1997, Tagamet HB in June 1998.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO PLANNING PRIVATE LABEL OTC NAPROXEN SODIUM FOR EARLY 1997 LAUNCH, VP-Business and Product Development Carl Johnson told the Dillon Read Generic Drug & Drug Delivery Conference in New York City May 7. "We have successfully completed a biostudy" on an equivalent Aleve product, Johnson reported. "We have filed our ANDA and it has been accepted, and we're very confident that we will be in a position to ship this product when the marketing exclusivity period expires early in 1997."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning